Member Info for ciaskin

Hi Marcus. Good to see you posting on LSE. Your well-researched posts on 'the other place' have often been reposted or cross-referred here but it's great to read your thoughtful contributions first hand.

And yes, that NHS link from April really serves to remind us what we're sitting on!

Valuation increased to £373m or 36p/share; cash through to H226 Our iSCIB1+ valuation is essentially doubled to 8p/share, largely on higher peak sales, together with a longer patent life and a modest de-risking. With all else being equal, this results in an uplift to our Scancell rNPV to £373m (from £330m), or 36p/share, with further upside on upcoming clinical news. The cash runway extends into H226.

Last RNS.. Mary Ann Chang is the IR contact listed in the footer - with a Scancell email address.

1,000,000 and 616,500 at 10.875p. Must be buys at that price...?

"These data demonstrate that we can add iSCIB1+ to the combination of nivolumab and ipilimumab, or potentially combine it with pembrolizumab, to produce a marked benefit for patients with advanced melanoma"

Smart thinking. GLA.

The sub-headline "12-month progression-free survival also markedly improved, with a 20% increase over standard of care" also rather understates things, in my opinion. Cohort 1's 64.6% v. SOC 43.9% is almost half as much again - an IMPROVEMENT of 47%. And Cohort 3's 80.8% PFS figure is almost DOUBLE that of standard of care.(

We want discussion today - not disruption - so don't even give him the oxygen of acknowledgement...

"Cohort 3 demonstrated 11-month PFS of 80.8%. These compare favorably to previously reported PFS of 43.9% for ipilimumab plus nivolumab at 12 months."

Cohort 3 is iScib1 +...

"Cohort 3 demonstrated 11-month PFS of 80.8%. These compare favorably to previously reported PFS of 43.9% for ipilimumab plus nivolumab at 12 months."

Cohort 3 is iScib1 +...

Great results and webinar at 1pm today

Just published at:

https://www.linkedin.com/pulse/cancer-vaccine-bulletin-july-edition-dr-lennard-lee-dphil-frcp-nlfge

It's a really good resource, free to follow on LinkedIn and its author, Lennard Lee is receptive to article ideas. (DNA Vs MRNA, anyone?)

This edition also includes a nice name check for our Lindy, who won the award for Innovation in Cancer Vaccine Development.

Equally, if an SP rise/re-rate is expected as a result of the imminent news, then then that is a VERY good reason to turn share options into actual shares right now. (IMHO).

Either way, it's almost time to take your seats ladies and gentlemen; the show is about to begin...!

We should know soon enough. SXS put out the RNS about KKR considering a counter offer almost immediately after the original Advent bid, so if they are to come back to the table, I would expect it in the next couple of days or Monday latest...

£40 a share. Will Advent come back with a counter offer? Or might it flush out other suitors? Enjoy the ride - good luck all!

Scancell have always been understated IMHO. (Still, far better to under-promise and over-deliver rather than the other way round... )

Professional and confident presentation by all three but Nermeen was especially impressive, I thought...

...parent company for Glymab Therapeutics Ltd?

Also, it not just a simple parent:child relationship? Just as Scancell Holdings is the parent company of Scancell Ltd, it is now simple the parent com

Yes, and Glymab Therapeutics is a much better name than Zakari Therapeutics - for those here long enough to remember!

Invitation just received from Investor Meet Company : 2.30 on Thursday 24th.

Stars aligning??

Have a great weekend everyone!

"Scancell is the first British company to join the CVLP, and iSCIB1+ is the first DNA vaccine to be part of this initiative."

ABOUT TIME!!

Good luck all...